Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Girentuximab PET in Urothelial Cancer (ZiPUP)
NCT05046665Phase 1Completed
- Sponsor
- South Metropolitan Health Service
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 89Zr-DFO-girentuximab in urothelial carcinoma (UC), sponsored by South Metropolitan Health Service. Primary endpoint: Sensitivity and Specificity of 89Zr-girentuximab PET compared with FDG PET at Day 90. Started May 2021; status: completed.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05046665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046665.